We are a start-up biotech in Bryan/College Station, Texas, developing novel oral therapies for chronic diseases. Launched in 2024 and leveraging a strong partnership with Texas A&M University, Krateos Therapeutics focuses on advancing its lead candidates through preclinical development to human trials.